NCT04915612View on ClinicalTrials.gov

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER